Monopar Therapeutics (NASDAQ:MNPR) Stock Falls 5.3% Following Insider Selling

Key Points

• Monopar Therapeutics shares fell 5.3% to about $79.27 after CEO Chandler Robinson sold 29,056 shares for approximately $2.56 million under a pre-arranged Rule 10b5-1 trading plan. His ownership declined 22.64% following the sale.
• Analysts remain broadly positive, with the stock carrying a “Moderate Buy” consensus rating and an average price target of $121.36, despite some recent rating downgrades.
• The clinical-stage biopharmaceutical company reported quarterly EPS of negative $0.62, slightly better than estimates, while developing camsirubicin as a potential cancer treatment designed to reduce heart-related toxicity.

Shares of Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) were down 5.3% on Tuesday after an insider sold shares in the company. The company traded as low as $79.54 and last traded at $79.2650. Approximately 102,103 shares changed hands during trading, a decline of 52% from the average daily volume of 211,707 shares. The stock had previously closed at $83.72.

Specifically, CEO Chandler Robinson sold 29,056 shares of the firm's stock in a transaction dated Thursday, September 24th. The shares were sold at an average price of $88.00, for a total transaction of $2,556,928.00. Following the completion of the sale, the chief executive officer owned 99,267 shares in the company, valued at approximately $8,735,496. This trade represents a 22.64% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Analyst Ratings Changes

A number of research analysts have weighed in on MNPR shares. UBS Group set a $125.00 target price on shares of Monopar Therapeutics in a research note on Thursday, July 23rd. Wall Street Zen upgraded shares of Monopar Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, September 12th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Monopar Therapeutics in a report on Friday, July 17th. Piper Sandler set a $105.00 price objective on Monopar Therapeutics in a research note on Tuesday, June 2nd. Finally, Cantor Fitzgerald lowered Monopar Therapeutics from an "overweight" rating to a "neutral" rating and increased their price objective for the company from $109.00 to $119.00 in a report on Thursday, August 13th. Two analysts have rated the stock with a Strong Buy rating, seven have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $121.36.

Monopar Therapeutics Price Performance

The stock has a market capitalization of $531.87 million, a P/E ratio of -36.71 and a beta of 1.49. The stock has a fifty day moving average price of $109.77 and a 200 day moving average price of $82.32.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.64) by $0.02. Research analysts anticipate that Monopar Therapeutics Inc. will post -2.98 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Siren L.L.C. lifted its position in Monopar Therapeutics by 27.2% in the first quarter. Siren L.L.C. now owns 270,118 shares of the company's stock valued at $14,800,000 after purchasing an additional 57,820 shares during the last quarter. ADAR1 Capital Management LLC boosted its position in shares of Monopar Therapeutics by 13.0% during the first quarter. ADAR1 Capital Management LLC now owns 264,278 shares of the company's stock valued at $14,480,000 after purchasing an additional 30,370 shares in the last quarter. Bank of New York Mellon Corp lifted its position in Monopar Therapeutics by 21.2% during the first quarter. Bank of New York Mellon Corp now owns 78,618 shares of the company's stock valued at $4,307,000 after buying an additional 13,761 shares during the period. Walleye Capital LLC bought a new stake in shares of Monopar Therapeutics during the 1st quarter valued at $3,458,000. Finally, Bank of America Corp DE boosted its holdings in shares of Monopar Therapeutics by 838.2% during the 1st quarter. Bank of America Corp DE now owns 59,699 shares of the company's stock valued at $3,271,000 after buying an additional 53,336 shares in the last quarter. Hedge funds and other institutional investors own 1.83% of the company's stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel treatments for cancer. The company's programs are designed to address significant limitations associated with existing cancer therapies, including treatment resistance and dose-limiting toxicity.

Monopar's lead clinical program is camsirubicin, an investigational next-generation anthracycline being developed for patients with advanced soft tissue sarcoma. The drug is designed to retain the anticancer activity of anthracyclines while reducing the risk of cumulative heart damage associated with conventional doxorubicin.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.